Cachexia—a syndrome characterized by progressive muscle wasting—affects both humans and dogs with chronic diseases such as cancer. A recent study in Molecular Oncology found that lower circulating levels of certain microRNAs—small non-coding RNAs that regulate gene expression—often indicate the presence of cachexia in senior dogs.
For the study, researchers analyzed blood levels of numerous microRNAs in 25 senior dogs. Decreased levels of miR-15a, miR-15b, miR-16, and miR-140 were indicators of cachexia associated with cancer, with miR-16 being the most robust individual marker. A sex-specific analysis revealed that miR-140, a microRNA with anti-inflammatory properties, was significantly lower in female dogs with cancer (mostly mammary gland and reproductive tract tumors) compared with those without cancer, and even lower in those with cachexia in addition to cancer. These findings suggest that estrogen-related cancer and cachexia may represent two distinct pathological processes that converge to suppress miR-140’s expression.
“Our findings show that specific circulating microRNAs, especially miR-16 and miR-140, may provide important clues for detecting cancer-associated cachexia in senior dogs,” said corresponding author Kyu-Shik Jeong, DVM, PhD, of Daegu Haany University, in the Republic of Korea. “Because dogs closely share biological and environmental features with humans, this study may help open the door to earlier diagnosis, better monitoring, and future therapeutic strategies for cancer-related muscle wasting in both veterinary and human medicine.”
URL: https://onlinelibrary.wiley.com/doi/10.1002/1878-0261.70293
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Molecular Oncology is an open access journal owned by FEBS. The journal considers Research Articles from the fields of basic, translational, and clinical cancer research. We also publish Review Articles, Commentaries and Policy Papers discussing emerging concepts in cancer research, cancer diagnosis, prevention and care. Journal profits are re-invested in the scientific community. Manuscripts are handled by a team of dedicated academic Section Editors under a transparent peer review scheme.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.